JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
BRISBANE, Calif., May 03, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it will host a company overview webinar on Wednesday, May 10, 2017, at 1:30 p.m. ET.
Dr. Cameron Durrant, chairman and CEO, will present an update on the company, its growth initiative progress and upcoming key milestones. The webinar will feature a presentation that can be accessed via the webcast link below. A question-and-answer session will follow.
Date: Wednesday, May 10, 2017
Time: 1:30 p.m. ET (10:30 a.m. PT)
Dial-in: 1-888-267-6301
Toll/International Dial-in: 1-719-457-2734
Webcast: http://public.viavid.com/index.php?id=124313
A telephone replay will be available approximately two hours after the call through June 10, 2017. Access the replay by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from international locations, and entering the replay pin number: 8563194.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab, for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
